Duke Human Vaccine Institute to partner with RTI International as Coordinating Center for newly established NIAID-funded Emerging Infectious Diseases Network
The Duke Human Vaccine Institute in partnership with RTI International have been named the coordinating center for the newly established Centers for Research in Emerging Infectious Diseases (CREID) network, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID). The coordinating center will serve as the network’s operational hub to streamline and accelerate research response to emerging infectious disease outbreaks.
RTI International to Serve as Coordinating Center for Newly Established NIAID-funded Emerging Infectious Diseases Network
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded RTI International, a nonprofit research institute, in partnership with the Duke Human Vaccine Institute, the coordinating center role for the newly established Centers for Research in Emerging Infectious Diseases (CREID) network. The CREID Coordinating Center will serve as the network’s operational hub to streamline and accelerate research response to emerging infectious disease outbreaks.
NIAID Establishes Centers for Research in Emerging Infectious Diseases
The National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health, today announced that it has awarded 11 grants with a total first-year value of approximately $17 million to establish the Centers for Research in Emerging Infectious Diseases (CREID).
Meet the team powering Duke's COVID-19 surveillance testing efforts
Students returning to Duke University are participating in surveillance testing to help rapidly identify and isolate people who may have contracted the COVID-19 virus. This is done using pool testing, which combines nasal samples from five people for a single test to allow more testing using fewer resources. If a pooled test comes back positive, each student in that sample will be tested individually to identify who has contracted the virus and follow through with any isolation procedures.
UNC, Duke seek volunteers, particularly people of color, for COVID-19 vaccine trials
UNC Health and the School of Medicine are looking for 500 people willing to test a potential vaccine for COVID-19, one of what could be several opportunities for Triangle residents to take part in vaccine clinical trials for coronavirus in the coming months.
This might be your most important flu shot ever
This fall and winter, health experts expect two types of deadly viruses to be circulating widely in the US. But they don’t yet know what the extent of the damage will be when the two collide.
Keeping a Close Watch on COVID-19 with Surveillance Tests
Duke Associate Professor of Biology Steve Haase likes to compare the spread of COVID-19 to the haphazard advance of a forest fire, where tiny glowing embers, which he likens to the virus, drift in the air, among trees bringing potential harm whatever they touch.
Duke Institute Tapped to Test Monoclonal Antibody Preventative for COVID-19
The Duke Human Vaccine Institute Pandemic Prevention Program (DHVI-P3) has received an additional $7.6 million in federal funding to manufacture and test in humans a neutralizing monoclonal antibody for the prevention of COVID-19.
Experts express doubts over Russia's vaccine claim
Russian President Vladimir Putin announced Tuesday that his country has developed the first-ever coronavirus vaccine, but many experts doubt its legitimacy.
Duke Team to Implement SARS-CoV-2 Neutralization Assay Concordance Survey in Laboratories Worldwide
The Duke EQAPOL/VQA team, led by Tom Denny in partnership with Dr. David Montefiori in the Department of Surgery, will implement a SARS-CoV-2 Neutralization Assay Concordance Survey (SNACS) in more than 50 participating laboratories worldwide.